GNE-493

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H20N6O2S
Molecular Weight	372.445
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(O)C1=CC2=NC(=NC(N3CCOCC3)=C2S1)C4=CN=C(N)N=C4

InChI

InChIKey=LEXMMFPAPDGYGZ-UHFFFAOYSA-N

InChI=1S/C17H20N6O2S/c1-17(2,24)12-7-11-13(26-12)15(23-3-5-25-6-4-23)22-14(21-11)10-8-19-16(18)20-9-10/h7-9,24H,3-6H2,1-2H3,(H2,18,19,20)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21985639

GNE-493 is a potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor for the treatment of cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
PI3-kinase p110-alpha subunit 41 Target ID: CHEMBL4005 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669	Inhibitor 8504	3.4 nM [IC50]
Serine/threonine-protein kinase mTOR 35 Target ID: CHEMBL2842 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669	Inhibitor 8504	30.0 nM [IC50]
PI3-kinase p110-beta subunit 31 Target ID: CHEMBL3145 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669	Inhibitor 8504	12.0 nM [IC50]
PI3-kinase p110-delta subunit 43 Target ID: CHEMBL3130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669	Inhibitor 8504	16.0 nM [IC50]
PI3-kinase p110-gamma subunit 32 Target ID: CHEMBL3267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669	Inhibitor 8504	16.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.	2010-02-11	20050669

Patents

Sample Use Guides

In Vivo Use Guide

Mice bearing MCF7.1 breast cancer xenografts were dosed orally once daily with 10 mg/kg GNE-493

Route of Administration: Oral

In Vitro Use Guide

GNE-493 inhibited PI3K/mTOR with IC50s of 3.4/12/16/16/30 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively, assessed as PIP3 product formation by fluorescence polarization assay.

Name

Type

Language

GNE-493

Common Name

English

THIENO(3,2-D)PYRIMIDINE-6-METHANOL, 2-(2-AMINO-5-PYRIMIDINYL)-.ALPHA.,.ALPHA.-DIMETHYL-4-(4-MORPHOLINYL)-

Preferred Name

English

Code System Code Type Description

FDA UNII

0L843LS9YK

Created by admin on Mon Mar 31 22:08:22 GMT 2025 , Edited by admin on Mon Mar 31 22:08:22 GMT 2025

PRIMARY

CAS

1033735-94-2

Created by admin on Mon Mar 31 22:08:22 GMT 2025 , Edited by admin on Mon Mar 31 22:08:22 GMT 2025

PRIMARY

PUBCHEM

25242324

Created by admin on Mon Mar 31 22:08:22 GMT 2025 , Edited by admin on Mon Mar 31 22:08:22 GMT 2025

PRIMARY

ACTIVE MOIETY


					0L843LS9YK

GNE-493

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20050669Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21985639

Originator

Approval Year

Targets

Conditions

Approved Use

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20050669
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21985639